Effects of Hepatitis B Virus Infection on Patients with COVID-19: A Meta-Analysis

Yu, Yang; Xing-zhao, LI; Wan, Taihu

doi:10.1007/s10620-022-07687-2

Cited by 13 publications

(8 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Limited data on SARS-CoV-2 infections in patients with chronic HBV and HCV infection show conflicting results. For example, in HBV/SARS-CoV-2 co-infected patients, some studies have reported a higher severity and mortality of COVID-19 compared with the general population,63 64 while this has not been observed by others 65 66. Similarly, in HCV/SARS-CoV-2 co-infection, some reports have indicated a similar COVID-19 outcome compared with healthy individuals,67 while others have shown a higher SARS-CoV-2-associated mortality in HCV-infected patients 68…”

Section: Sars-cov-2 and Clinical Impact On Cldmentioning

confidence: 97%

SARS-CoV-2 and the liver: clinical and immunological features in chronic liver disease

Luxenburger

Thimme

2023

Gut

View full text Add to dashboard Cite

SARS-CoV-2 infection may affect the liver in healthy individuals but also influences the course of COVID-19 in patients with chronic liver disease (CLD). As described in healthy individuals, a strong SARS-CoV-2-specific adaptive immune response is important for the outcome of COVID-19, however, knowledge on the adaptive immune response in CLD is limited.Here, we review the clinical and immunological features of SARS-CoV-2 infection in individuals with CLD. Acute liver injury occurs in many cases of SARS-CoV-2 infection and may be induced by multiple factors, such as cytokines, direct viral infection or toxic effects of COVID-19 drugs. In individuals with CLD, SARS-CoV-2 infection may have a more severe course and promote decompensation and particularly in patients with cirrhosis. Compared with healthy individuals, the SARS-CoV-2-specific adaptive immune responses is impaired in patients with CLD after both, natural infection and vaccination but improves at least partially after booster vaccination.Following SARS-CoV-2 vaccination, rare cases of acute vaccine-induced liver injury and the development of autoimmune-like hepatitis have been reported. However, the concomitant elevation of liver enzymes is reversible under steroid treatment.

show abstract

Section: Sars-cov-2 and Clinical Impact On Cldmentioning

confidence: 97%

SARS-CoV-2 and the liver: clinical and immunological features in chronic liver disease

Luxenburger

Thimme

2023

Gut

View full text Add to dashboard Cite

show abstract

“…Sepsis is one of the most common serious complications caused by infectious diseases, which is a very important public health problem with a high fatality rate [17, 21]. Previous studies have shown that coinfection of hepatitis B patients with other viruses may be associated with poorer clinical course [10, 15, 22]. It is not clear whether there is a possibility of worse outcomes after sepsis in patients with hepatitis B infection.…”

Section: Discussionmentioning

confidence: 99%

“…Hepatitis B is a major global public health problem, and despite impressive progress in preventing chronic infections and reducing mortality, hepatitis B virus (HBV) infection remains a leading cause of premature death [6]. Chronic HBV infection was prone to coinfection with pathogens including bacteria and viruses [7][8][9][10]. In disease states of chronic viral infection, persistent T-cell receptors and inflammatory signalling drive CD8 + T cells into a state of dysfunction, leading to CD8 + T-cell depletion [11].…”

Section: Introductionmentioning

confidence: 99%

“…In addition, T-cell depletion was one of the manifestations of sepsis immunosuppression [12][13][14]. Some studies have shown that complicating chronic hepatitis B was associated with poor prognosis in coronavirus disease 2019 (COVID-19) patients [10,15]. Bacterial infection (BI) was associated with high levels of HBV replication [7], and in patients with HBV-related acute-on-chronic liver failure, BI can worsen liver failure and lead to adverse clinical outcomes [16].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association of current hepatitis B virus infection with mortality in adults with sepsis

Gao

et al. 2023

Epidemiol. Infect.

View full text Add to dashboard Cite

This study aimed to determine the impact of current hepatitis B virus (HBV) infection on patients hospitalised with sepsis. This was a retrospective cohort study. Patients from three medical centres in Suzhou from 10 January 2016 to 23 July 2022 participated in this study. Demographic characteristics and clinical characteristics were collected. A total of 945 adult patients with sepsis were included. The median age was 66.0 years, 68.6% were male, 13.1% presented with current HBV infection, and 34.9% of all patients died. In the multivariable-adjusted Cox model, patients with current HBV infection had significantly higher mortality than those without (hazard ratio (HR) 1.50, 95% confidence interval (CI) 1.11–2.02). A subgroup analysis showed that being infected with HBV significantly increased in-hospital mortality in patients younger than 65 years old (HR 1.74, 95% CI 1.16–2.63), whereas no significant impact was observed in patients ≥65 years. The propensity score-matched case–control analysis showed that the rate of septic shock (91.4% vs. 62.1%, P < 0.001) and in-hospital mortality (48.3% vs. 35.3%, P = 0.045) were much higher in the propensity score-matched HBV infection group compared with the control group. In conclusion, current HBV infection was associated with mortality in adults with sepsis.

show abstract

“…Most studies that have examined the influence of HBV on COVID-19 prognosis have been conducted in China due to the high prevalence of HBV in the country[ 60 ]. Yu et al [ 61 ] reported higher in-hospital mortality, more severe disease, and liver function abnormalities in COVID-19 patients infected with HBV compared to COVID-19 patients without HBV. However, the presence of COVID-19 infection or treatment with tocilizumab or corticosteroids could reactivate hepatitis B infection[ 49 , 62 ].…”

Section: Covid-19 In Patients With Pre-existing Liver Diseasementioning

confidence: 99%

Outcomes of COVID-19 among patients with liver disease

Vujčić¹

2023

World J Gastroenterol

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is primarily a respiratory disease with multi-organ involvement, including impaired liver function. It has been noticed that a significant proportion of COVID-19 patients have liver dysfunction, especially those with a more severe disease course. The coronavirus causes direct damage to the liver using the angiotensin-converting enzyme 2, a cell-surface receptor for cellular entry, that is expressed in the liver. According to previous research, liver enzyme abnormalities were observed in a considerable proportion of COVID-19 patients, and elevated liver transaminases were found in about 20% of these patients, alkaline phosphatase in 6.1%, and gamma-glutamyl transferase in 21.1%. COVID-19 might trigger a deterioration of liver function in patients with pre-existing chronic liver diseases (CLDs) and also in those without previous liver disorders. The majority of COVID-19 patients who develop liver injury are men, the elderly, and those with a higher body mass index. Compared to the general population, COVID-19 is associated with significant morbidity and mortality in patients with liver disease (cirrhosis and liver transplantation recipients). However, some studies indicate that CLDs have a lesser role in determining patient progression towards higher disease severity.

show abstract

Effects of Hepatitis B Virus Infection on Patients with COVID-19: A Meta-Analysis

Cited by 13 publications

References 63 publications

SARS-CoV-2 and the liver: clinical and immunological features in chronic liver disease

SARS-CoV-2 and the liver: clinical and immunological features in chronic liver disease

Association of current hepatitis B virus infection with mortality in adults with sepsis

Outcomes of COVID-19 among patients with liver disease

Contact Info

Product

Resources

About